1. Introduction {#sec1}
===============

The incidence of*Pneumocystis jirovecii* pneumonia (PCP), a disease commonly occurring in patients with acquired immunodeficiency syndrome, has been increasing in patients without human immunodeficiency virus (HIV) infection as immunosuppressive medications become more widely used. Mortality of PCP depends upon the underlying disease and has been increasing \[[@B1]\], being 10% in HIV-positive and 30--60% in HIV-negative disease \[[@B2], [@B3]\]. Although the reasons for these differences in mortality rates are not yet fully understood, neutrophil counts in bronchoalveolar lavage fluid are significantly higher in HIV-negative than HIV-positive patients with PCP \[[@B4]\]. The symptoms of PCP are more abrupt and the incidence of tracheal intubation was 10-fold higher in HIV-negative than in HIV-positive patients \[[@B5]\], suggesting that more intense inflammatory responses develop in HIV-negative patients \[[@B2], [@B5]\].

In contrast, the overall mortality rate of PCP patients who required mechanical ventilation (MV) was reported to be 50% to 60% regardless of HIV infection \[[@B5]\]. In HIV-negative patients, increased mortality rate was associated with positive end-expiratory pressure (PEEP) on the first three days of acute respiratory failure \[[@B6]\] and the development of pneumothorax during MV \[[@B7], [@B8]\]. MV was a risk factor for the poor prognosis of patients with severe PCP \[[@B1], [@B2], [@B5], [@B7]--[@B9]\], but whether or not MV is simply a marker of severity or itself is harmful in PCP patients is unclear. The finding, that noninvasive positive pressure ventilation (NPPV) decreased the incidence of pneumothorax \[[@B10], [@B11]\], indicates that invasive ventilation may be causing harm. However, the association of the modalities of MV during invasive and noninvasive ventilation with the incidence of pneumothorax has never been investigated. Because two-thirds of patients presenting with acute respiratory failure required MV \[[@B12]\], the role of MV as a therapeutic modality should be investigated further.

We therefore retrospectively evaluated the effects of MV on 90-day mortality in HIV-negative patients with acute respiratory failure caused by PCP in our hospital. We sought the underlying conditions, clinical and laboratory features, ventilator settings, the incidence of tracheal intubation, and the adverse events during MV to assess the risk factors associated with poor patient prognosis.

2. Methods {#sec2}
==========

2.1. Subjects {#sec2.1}
-------------

A retrospective chart review was performed of all patients admitted to our multidisciplinary general intensive care unit (ICU) from December 2008 until January 2012 who were diagnosed with PCP and treated for acute hypoxemic respiratory failure with any types of MV.

2.2. Diagnosis of PCP {#sec2.2}
---------------------

Patients were suspected of PCP infection if they had a history of immunosuppressant use and manifested acute-onset dyspnea and hypoxemia at admission and if chest radiographs showed bilateral opacities. PCP was diagnosed by fluorescent antibody staining (Fungi-Fluor Kit Pneumocystis Kit, Polysciences Inc.) using induced sputum or bronchoalveolar lavage fluid. Results were checked by a trained laboratory technician and confirmed by the board-certified infection control doctors.

2.3. Treatment for PCP {#sec2.3}
----------------------

### 2.3.1. Medication {#sec2.3.1}

Intravenous administration of a combination of trimethoprim (15 mg/kg) and sulfamethoxazole (75 mg/kg) plus methylprednisolone was started immediately after the diagnosis of PCP. The dose of methylprednisolone was dependent on the prior dosage of steroids and any underlying diseases.

### 2.3.2. Mechanical Ventilation {#sec2.3.2}

Because a specialized protocol of MV for PCP has not been developed, we used the MV protocol for acute hypoxemic respiratory failure without hypercapnia in our ICU. Briefly, NPPV was initiated with 7 cmH~2~O of continuous positive airway pressure (CPAP) and 1.0 of FIO~2~ via facemask using NPPV machine (BiPAP VISION, Fuji Respironics, Tokyo) when supplemental oxygen failed to maintain percutaneous oxygen saturation (SpO~2~) over 90%. Biphasic positive airway pressure (BIPAP) and pressure support ventilation (PSV) were not used during noninvasive ventilation. When NPPV was contraindicated, 12 cmH~2~O of CPAP failed to improve hypoxemia, or delayed intubation may put the patient at risk for adverse outcome as expected by an attending physician, MV was administered via tracheal intubation using an ICU-type ventilator (Evita-XL, Draeger Medical, Germany). CPAP or airway pressure release ventilation (APRV) with automatic tube compensation was used depending on the gas exchange. PEEP was titrated to maintain FIO~2~ as low as possible. CPAP was converted to APRV when PEEP of 18 cmH~2~O did not maintain PaO~2~ \> 60 mmHg or when respiratory acidosis was observed. APRV was applied according to the previous review \[[@B13]\]. Briefly, PEEP (*P*~high~) was titrated to maintain acceptable oxygenation. The *T*~high~ was set to prevent hypercapnia or respiratory acidosis. *P*~low~ was zero and *T*~low~ was set to achieve ratios of termination of peak expiratory flow rate to peak expiratory flow rate of 50 to 75%.

### 2.3.3. Data Collection {#sec2.3.3}

The following data were collected: general demographic information; underlying diseases including HIV status; underlying immunosuppressive conditions; time from the onset of pneumonia to the start of PCP treatment; medications used to treat PCP; laboratory analysis, including serum 1,3-*β*-D-glucan, lactate dehydrogenase (LDH), KL-6, and surfactant protein (SP)-D; acute physiological and chronic health evaluation (APACHE) II score at ICU admission; MV parameters; incidence of tracheal intubation; duration of MV, ICU stay, and hospital stay; and overall hospital mortality. Serum 1,3-*β*-D-glucan was measured using FangitecG MK (Seikagaku Corp.), with a cutoff of 20 pg/mL, a value set by our institution\'s laboratory department.

### 2.3.4. Statistical Analysis {#sec2.3.4}

Statistical analyses were performed using JMP 9 (SAS Institute Inc., Cary, NC, USA). Proportion was used as descriptive statistics for categorical variables and mean ± SD or median (interquartile range (IQR)) for quantitative variables. Between-group differences were compared using Fisher\'s exact test for qualitative variables. A *t*-test or Mann--Whitney *U* test was used to compare quantitative variables, as appropriate. All variables that had a *p* value below 0.2 in the univariate analysis were entered into a stepwise multivariate analysis. All tests were two-tailed. Statistical significance was defined as *p* \< 0.05.

3. Results {#sec3}
==========

3.1. Demographic Data {#sec3.1}
---------------------

During the study period, we suspected that 28 patients had PCP, based on their symptoms, radiographs, and history of underlying disease. Of these, 21 patients were diagnosed with PCP, and 20 (95%) required MV.

Demographic data of all patients are shown in [Table 1](#tab1){ref-type="table"}. Nine patients had rheumatoid arthritis (RA) or other collagen vascular diseases, and seven were renal transplant recipients. Twelve patients (60%) were female, including all nine with RA. None of the study subjects was HIV-positive. Although all the patients had received chemoprophylaxis for PCP when the immunosuppression was initially started, the regimen of immunosuppressants was changed or stopped at some stages in each patient. No patients included in the study were given any chemoprophylaxis just before the onset of PCP. Patients with RA/collagen disease received 7.0 (2.9, 10.0) mg methotrexate per week. None of these patients received any biologic agents within one year before PCP infection. Basic immunosuppressants in renal transplant recipients included mycophenolate mofetil and tacrolimus or cyclosporin. Prednisolone-equivalent dose in patients with RA/collagen disease and renal transplants was 3.0 (1.3, 7.8) and 5.0 (5.0, 8.2) mg/day, respectively. Treatment started 3.5 (1.0, 7.0) days after admission.

3.2. MV Parameters and Duration {#sec3.2}
-------------------------------

NPPV was used in 19 patients. Eleven patients (55%) were switched to tracheal intubation because of the failure of NPPV (7 cases), sustained NPPV (3), or the development of pneumothorax (1). One patient could not tolerate the facemask and was intubated without NPPV. PEEP level at days 1, 3, and 5 was 10.0 (8.0, 10.5), 10.0 (8.0, 14.3), and 10.0 (8.0, 14.0) cmH~2~O, respectively. Durations of NPPV, tracheal intubation, and MV were 3.5 (1.0, 9.3), 5.0 (0.0, 12.3), and 10.0 (5.0, 15.5) days, respectively. The longest duration of MV including NPPV was 71 days in a patient who survived. Eight patients (40%) did not require the intubation; their CPAP level on day 1 was 7.5 (6.8, 8.0) cmH~2~O and their duration of NPPV was 5.5 (3.8, 9.3) days.

3.3. Serum Biomarkers at ICU Admission {#sec3.3}
--------------------------------------

Serum 1,3-*β*-D-glucan, LDH, KL-6, and SP-D at ICU admission were presented in [Table 2](#tab2){ref-type="table"}. Data in total and two major subgroups, RA/collagen disease patients and renal transplantation recipients, were listed. Serum 1,3-*β*-D-glucan concentration was significantly lower in RA/collagen than in renal transplant recipients.

3.4. Outcomes {#sec3.4}
-------------

Four patients (20%) died in the hospital, all of whom had received tracheal intubation. Three had RA, with two of the three having interstitial lung disease (ILD). These two patients were initially weaned from NPPV on days 4 and 7, but ILD worsened on days 6 and 8, respectively. NPPV was restarted, but tracheal intubation was performed on days 10 and 21. One RA patient was intubated due to the development of pneumothorax on day 11. All three patients showed no improvement of oxygenation after intubation and died. The remaining nonsurvivor had nephrotic syndrome and liver cirrhosis (Child-Pugh grade C). On admission, the patient presented acute kidney injury. She was intubated on day 2 and died of liver failure.

Sixteen patients (80%) survived, including all seven renal transplant recipients. One RA patient with ILD survived without acute exacerbation. Their duration of MV and length of hospitalization were 10.0 (54.0, 13.5) days and 24.0 (19.0, 40.5) days, respectively.

3.5. Multivariate Analysis of Prognostic Factors for 90-Day Mortality {#sec3.5}
---------------------------------------------------------------------

Analysis between survivors and nonsurvivors was shown in [Table 3](#tab3){ref-type="table"}. Nonsurvivors were older and had lower serum albumin levels at baseline compared with survivors. Multivariate analysis demonstrated that the incidence of ILD as an underlining disease \[odds ratio (OR) 15; 95% CI 1.01--438.0; *p* = 0.0488\] and serum KL-6 \[OR 1.0025; 95% CI 1.000504--1.000667; *p* = 0.0052\] were independently associated with 90-day mortality. The need for tracheal intubation, that is, NPPV failure, and PEEP levels in the first five days were not associated with death.

4. Discussion {#sec4}
=============

In this study, we found lower mortality rate in mechanically ventilated patients with PCP compared with those reported in previous studies. Also, our study showed that PEEP during the first five days of MV was not associated with 90-day mortality, unlike a previous report \[[@B6]\]. Patients with RA who had ILD showed higher mortality. KL-6 at baseline was greater in nonsurvivors than in survivors. Only one patient (5%) developed pneumothorax during MV.

Previous studies have reported that the survival rate of PCP patients who required MV was quite low. For example, mortality rates were reported to be 76% in intubated patients and 91% in patients switched from NPPV to tracheal intubation \[[@B7]\]. Similarly, another study found that 3 of 4 intubated RA patients died, whereas all 12 patients without RA were intubated but survived after MV, and the mortality of RA patients was significantly low compared with non-RA patients \[[@B14]\]. Three of 4 nonsurvivors in RA had existing pulmonary fibrosis and died of subsequent exacerbation of interstitial pneumonia after resolution of the PCP. Of 21 HIV-negative PCP patients who required NPPV, 15 (70%) were switched to tracheal intubation, with 13 of the latter (87%) dying after MV \[[@B12]\]. We found, however, that the mortality rate in intubated patients was 36%, lower than those in previous studies, despite similar intubation rate (60%).

The causes for the different mortality rate are not confirmed from the study. One possibility is the different MV strategy and complications. First, the incidence of pneumothorax in previous reports ranged from 13 to 61% \[[@B6], [@B8], [@B10], [@B12], [@B15], [@B16]\]. The morality rate of mechanically ventilated PCP patients with pneumothorax ranged from 38 to 100% \[[@B4], [@B5], [@B8], [@B12]\], and development of pneumothorax appeared as one of the predictors for poor prognosis in PCP patients with \[[@B7]\] or without HIV \[[@B8]\]. In a previous study, NPPV avoided tracheal intubation in 67% of patients and decreased the incidence of pneumothorax from 37.5% to 8.3% \[[@B10]\]. In our ICU, NPPV is a routine initial support for all patients with acute hypoxemic respiratory failure and may explain the low incidence of pneumothorax (5%). Lower mean airway pressure associated with CPAP and less ventilator dyssynchrony with CPAP and APRV may also decrease pneumothorax. In addition, it is reported that 71% of NPPV failed in HIV-negative patients \[[@B12]\]. Delayed intubation could contribute to higher mortality \[[@B7]\]. Studies have shown that the mortality of intubated patients ranged from 59% to 91% \[[@B5]--[@B8], [@B10], [@B17], [@B18]\]. We also intubated earlier than the previous studies \[[@B5]\], that is, before patients showed respiratory muscle fatigue, and that probably contributed to the lower mortality rate (36%) in our study. The result that intubation had no association with death supports our hypothesis. Second, PEEP plays an important role in treating PCP, which often decreases lung volume \[[@B19], [@B20]\]. We titrated PEEP to find the appropriate and safe level in each patient. The average was 10.5 to 11.4 cmH~2~O and no substantial adverse effects were observed. Although it is difficult to compare with previous studies, higher PEEP to maintain lung volume and decrease transpulmonary pressure might contribute to better outcome. Patient characteristics may also contribute to differences in mortality. Most patients in our study regularly visited our hospital clinics for the treatment of their baseline diseases. This may be responsible for earlier start of treatment (3.5 days) compared to the previous study (8.4 days) \[[@B6]\], reducing mortality rate.

Serum concentrations of 1,3-*β*-D-glucan, LDH, KL-6, and SP-D increased at ICU admission, as previously reported \[[@B21]\]. However, in our study 1,3-*β*-D-glucan in 3 of the 9 patients with RA was lower than 31.1 pg/mL, the cutoff proposed for a diagnosis of PCP \[[@B21]\]. Lower 1,3-*β*-D-glucan level in patients with RA was observed in the previous report \[[@B14]\]. PCP was still diagnosed and treated in these three patients despite the low 1,3-*β*-D-glucan levels preventing the progression of the disease. However, it is necessary to evaluate the measured values in consideration of the underlying disease.

ILD is a risk factor for PCP in patients with RA \[[@B22]\] and their prognosis worsened when ILD was exacerbated during treatment with biologics \[[@B23]\]. KL-6, a biomarker for interstitial inflammation in the lungs, at the onset of respiratory failure was significantly higher in nonsurvivors than in survivors. Therefore, KL-6 may be a potential predictor for the prognosis, especially in patients with RA and coexisting ILD. A previous study \[[@B24]\] reported higher levels of 1,3-*β*-D-glucan and KL-6 in PCP patients with HIV, but neither was associated with the mortality rate, probably because of the different underlying diseases and lower rate of MV. Higher levels of KL-6 and SP-D in our study indicate that the extent of epithelial injury from the interaction between underlying disease and MV may determine the mortality in patients with PCP presenting with acute respiratory failure.

This study has potential limitations. This is a retrospective case series study performed in a single center. The number of patients included was small. This study was not designed to compare between CPAP and mandatory ventilation. The mortality rate of renal transplant recipients has been decreasing \[[@B25]\] and the patient population of our study might affect the lower mortality. Despite these limitations, the mortality in our results was low and suggests a potential for improved prognosis.

5. Conclusions {#sec5}
==============

We found MV strategies to prevent pneumothorax including liberal use of noninvasive ventilation, and PEEP titration and disuse of mandatory ventilation may improve mortality in this setting. Underlying disease of interstitial lung disease was a risk factor and KL-6 may be a useful predictor associated with mortality in patients with RA. These findings will need to be validated in larger studies.
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###### 

Demographic characteristics of subjects.

  Case   Age   Underlying disease      PED (mg)   MTX (mg)   APACHE II   PaO~2~/FIO~2~ (mmHg)   PaCO~2~ (mmHg)   mPS (mg)   PEEP (cmH~2~O)   DON (days)   DOI (days)   DOV (days)   LOH (days)   Outcome         
  ------ ----- ----------------------- ---------- ---------- ----------- ---------------------- ---------------- ---------- ---------------- ------------ ------------ ------------ ------------ --------- ----- ----------
  1      66    RT                      5          0          21          131                    29.2             80         8                10           8            1            5            5         15    Survived
  2      52    RT                      10         0          20          106                    25.9             16         25               20           18           1            13           13        24    Survived
  3      66    RT                      5          0          23          277                    20.6             80         5                5            ---          3            0            3         14    Survived
  4      50    RT                      5          0          16          104                    29.8             80         12               18           12           1            9            10        54    Survived
  5      56    RT                      10         0          15          154                    27.0             80         7                12           10           14           0            14        27    Survived
  6      55    RT                      5          0          12          166                    21.8             80         10               10           14           11           10           20        102   Survived
  7      47    RT                      6.4        0          11          315                    23.1             80         7                5            ---          3            0            3         23    Survived
  8      79    RA, ILD                 5          10         16          150                    20.5             500        6                7            7            5            0            5         56    Survived
  9      69    RA                      0          2.5        15          162                    27.1             500        8                8            ---          4            0            4         30    Survived
  10     74    RA, ILD                 6          8          19          108                    34.5             500        8                10           10           11           31           42        42    Died
  11     65    RA                      0          10         21          113                    29.1             500        12               10           10           10           0            10        47    Survived
  12     79    RA                      8          4          23          202                    24.8             500        10               8            8            1            34           34        37    Died
  13     76    RA, ILD, asthma         3          16         18          177                    28.1             1000       10               10           10           10           21           31        32    Died
  14     66    RA                      2          12         19          186                    30.1             500        8                8            8            9            0            9         29    Survived
  15     37    SLE, APS, MCTD          7.5        0          24          123                    26.8             1000       10               15           13           1            0            6         27    Survived
  16     47    SLE, APS                14         0          21          262                    26.6             500        8                10           8            6            0            6         24    Survived
  17     76    NS, LC, hepatitis       15         0          29          95                     22.4             80         10               22           20           1            10           11        105   Died
  18     57    Stevens-Johnson Synd.   65         0          22          227                    29.5             80         20               16           15           5            66           71        178   Survived
  19     41    Ulcerative Colitis      25         0          18          140                    37.0             80         15               14           14           0            12           12        61    Survived
  20     86    Malignant lymphoma      45         0          18          125                    36.9             80         10               10           8            0            5            5         80    Survived

RT: renal transplantation; RA: rheumatoid arthritis; ILD: interstitial lung disease; SLE: Systemic Lupus Erythematosus; APS: anti-phospholipid antibody syndrome; MCTD: Mixed Connective Tissue Disease; NS: nephrotic syndrome; LC: liver cirrhosis; PED: prednisolone-equivalent dose; MTX: methotrexate; APACHE: acute physiologic and chronic health evaluation; mPS: methylprednisolone; PEEP: positive end-expiratory pressure; DON: duration of NPPV; DOI: duration of intubation; DOV: duration of ventilation; LOH: length of hospitalization.

###### 

Serum 1,3-*β*-D-glucan, LDH, KL-6, and SP-D levels at ICU admission in all patients and major subgroups. Data are presented as medians (interquartile range). RA: rheumatoid arthritis; LDH: lactate dehydrogenase; SP-D: surfactant protein-D.

                             Total (*n* = 20)        RA/collagen (*n* = 9)   Renal transplant (*n* = 7)   *p* value
  -------------------------- ----------------------- ----------------------- ---------------------------- -----------
  1,3-*β*-D-Glucan (pg/mL)   256.1 (64.4, 993.9)     71.4 (32.9, 206.3)      2600.0 (1121.5, 2880.0)      0.0043
  LDH (IU/L)                 468.5 (373.8, 588.5)    405.5 (338.0, 548.5)    498.0 (371.5, 539.0)         0.916
  KL-6 (U/mL)                650.5 (406.3, 1391.3)   409.0 (383.0, 1390.0)   565.0 (475.0, 983.0)         0.608
  SP-D (ng/mL)               193.0 (106.0, 445.0)    155.0 (95.2, 403.5)     193.0 (133.0, 216.0)         1.000

###### 

Comparison between nonsurvivors and survivors. Data are presented as patient number (%) and mean (SD) or medians (interquartile range) as appropriate.

                                                     Nonsurvivors (*n* = 4)   Survivors (*n* = 16)   *p* value
  -------------------------------------------------- ------------------------ ---------------------- -----------
  Age, year, mean (SD)                               76.2 (2.1)               58.7 (13.3)            0.0196
  Male, number (%)                                   0 (0%)                   8 (50%)                0.068
  APACHE II, mean (SD)                               22.2 (5.0)               18.2 (3.8)             0.093
  SAPS II, mean (SD)                                 40.0 (9.8)               36.7 (7.8)             0.486
  Underlying diseases, number (%)                                                                    
   Renal transplantation                             0 (0%)                   7 (43.7%)              0.101
   Rheumatoid Arthritis                              3 (75%)                  4 (25%)                0.061
   Interstitial lung disease                         2 (50%)                  1 (6.2%)               0.028
  PED (mg), median (range)                           7.0 (5.3, 9.8)           6.4 (5.0, 12.0)        0.528
  Methotrexate use (mg), median (range)              6.0 (3.0, 10.0)          0.0 (0.0, 0.6)         0.088
  Duration before treat (days), median (range)       1.5 (0.8, 4.0)           4.0 (1.8, 7.0)         0.629
  Duration before ARF (days), median (range)         1.5 (0.8, 4.0)           4.0 (2.0, 7.0)         0.565
  WBC (/*µ*L), mean (SD)                             7992.5 (1734.4)          9862.5 (3523.5)        0.323
  Albumin (g/dL), mean (SD)                          2.3 (0.5)                2.9 (0.4)              0.027
  *β*-D-Glucan (pg/mL), mean (SD)                    67.7 (70.6)              1158.9 (1448.2)        0.157
  LDH (U/L), mean (SD)                               424.2 (59.6)             511.3 (211.5)          0.434
  KL-6 (U/mL), mean (SD)                             2700.3 (1673.1)          738.7 (566.6)          0.002
  SP-D (ng/mL), mean (SD)                            1433.3 (1968.3)          220.3 (168.5)          0.042
  Worst P/F (mmHg), mean (SD)                        145.5 (52.2)             171.3 (65.1)           0.475
  PaCO~2~ on admission (mmHg), mean (SD)             27.5 (5.2)               27.6 (4.8)             0.968
  Tracheal intubation, number (%)                    4 (100%)                 8 (44%)                0.245
  Mechanical ventilation                                                                             
   PEEP day 1 (cmH~2~O), median (range)              10.0 (9.5, 10.0)         9.0 (7.8, 12.0)        0.668
   PEEP day 3 (cmH~2~O), median (range)              10.0 (9.5, 13.0)         10.0 (8.0, 14.3)       0.615
   PEEP day 5 (cmH~2~O), median (range)              10.0 (9.5, 12.5)         10.0 (8.0, 14.0)       0.711
   NPPV duration, days, median (range)               5.5 (1.0, 10.3)          3.5 (1.0, 6.8)         0.663
   Days of intubation, days, median (range)          26.0 (18.3, 31.8)        2.5 (0.0, 9.3)         0.077
   Days of ventilation, days, median (range)         32.5 (26.0, 36.0)        7.5 (5.0, 12.3)        0.068
  Pulse therapy of methylprednisolone, number (%)    3 (75.0%)                6 (37.5%)              0.177
  Length of hospitalization (days), median (range)   39.5 (35.8, 57.8)        29.5 (24.0, 57.3)      0.844

*Definition of Abbreviations*. APACHE, acute physiological and chronic health evaluation, SAPS; simplified acute physiological score, PED; prednisolone-equivalent dose, ARF; acute respiratory failure, WBC; white blood cell, LDH; lactate dehydrogenase, SP-D; surfactant protein-D, P/F; PaO~2~/FIO~2~, PEEP; positive end-expiratory pressure, NPPV; noninvasive positive pressure ventilation.
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